Human protein-protein interaction networks and the value for drug discovery

Drug Discovery Today

Volumn 12, Issue 17-18, 2007, Pages 709-716

  Ruffner, Heinz ^a   Bauer, Andreas ^a   Bouwmeester, Tewis ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN ARGININE METHYLTRANSFERASE;

AFFINITY PURIFICATION; DRUG RESEARCH; DRUG TARGETING; GENOME; HUMAN; MASS SPECTROMETRY; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; TECHNIQUE; YEAST; YEAST TWO HYBRID METHOD;

DRUG DESIGN; HUMANS; MASS SPECTROMETRY; PROTEIN ARRAY ANALYSIS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEINS; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 34548394483     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.07.011     Document Type: Review

References (49)

1. Fishman M.C., and Porter J.A. Pharmaceuticals: a new grammar for drug discovery. Nature 437 (2005) 491-493
2. Drewes G., and Bouwmeester T. Global approaches to protein-protein interactions. Curr. Opin. Cell Biol. 15 (2003) 199-205
3. Parrish J.R., et al. Yeast two-hybrid contributions to interactome mapping. Curr. Opin. Biotechnol. 17 (2006) 387-393
4. Vasilescu J., and Figeys D. Mapping protein-protein interactions by mass spectrometry. Curr. Opin. Biotechnol. 17 (2006) 394-399
5. Hultschig C., et al. Lehrach H: Recent advances of protein microarrays. Curr. Opin. Chem. Biol. 10 (2006) 4-10
6. Rain J.C., et al. The protein-protein interaction map of Helicobacter pylori. Nature 409 (2001) 211-215
7. Ito T., et al. A comprehensive two-hybrid analysis to explore the yeast protein interactome. Proc. Natl. Acad. Sci. U. S. A 98 (2001) 4569-4574
8. Uetz P., et al. A comprehensive analysis of protein-protein interactions in Saccharomyces cerevisiae. Nature 403 (2000) 623-627
9. Giot L., et al. A protein interaction map of Drosophila melanogaster. Science 302 (2003) 1727-1736
10. Li S., et al. A map of the interactome network of the metazoan C. elegans. Science 303 (2004) 540-543
11. Stelzl U., et al. A human protein-protein interaction network: a resource for annotating the proteome. Cell 122 (2005) 957-968
12. Rual J.F., et al. Towards a proteome-scale map of the human protein-protein interaction network. Nature 437 (2005) 1173-1178
13. Butland G., et al. Interaction network containing conserved and essential protein complexes in Escherichia coli. Nature 433 (2005) 531-537
14. Gavin A.C., et al. Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature 415 (2002) 141-147
15. Gavin A.C., et al. Proteome survey reveals modularity of the yeast cell machinery. Nature 440 (2006) 631-636
16. Ho Y., et al. Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry. Nature 415 (2002) 180-183
17. Krogan N.J., et al. Global landscape of protein complexes in the yeast Saccharomyces cerevisiae. Nature 440 (2006) 637-643
18. Ewing R.M., et al. Large-scale mapping of human protein-protein interactions by mass spectrometry. Mol. Syst. Biol. 3 (2007) 89
19. Zhu H., et al. Global analysis of protein activities using proteome chips. Science 293 (2001) 2101-2105
20. Selbach M., and Mann M. Protein interaction screening by quantitative immunoprecipitation combined with knockdown (QUICK). Nat. Methods 3 (2006) 981-983
21. Chang K., et al. Lessons from Nature: microRNA-based shRNA libraries. Nat. Methods 3 (2006) 707-714
22. Fewell G.D., and Schmitt K. Vector-based RNAi approaches for stable, inducible and genome-wide screens. Drug Discov. Today 11 (2006) 975-982
23. Ong S.E., and Mann M. Mass spectrometry-based proteomics turns quantitative. Nat. Chem. Biol. 1 (2005) 252-262
24. Blagoev B., et al. A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling. Nat. Biotechnol. 21 (2003) 315-318
25. Blagoev B., et al. Temporal analysis of phosphotyrosine-dependent signaling networks by quantitative proteomics. Nat. Biotechnol. 22 (2004) 1139-1145
26. Zhang Y., et al. Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. Mol. Cell Proteomics. 4 (2005) 1240-1250
27. Barabasi A.L., and Albert R. Emergence of scaling in random networks. Science 286 (1999) 509-512
28. He X., and Zhang J. Why do hubs tend to be essential in protein networks?. PLoS Genet. 2 (2006) e88
29. Goh K.I., et al. The human disease network. Proc. Natl. Acad. Sci. U. S. A 104 (2007) 8685-8690
30. Friedman A., and Perrimon N. Genetic screening for signal transduction in the era of network biology. Cell 128 (2007) 225-231
31. Massague J., et al. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103 (2000) 295-309
32. Colland F., et al. Functional proteomics mapping of a human signaling pathway. Genome Res. 14 (2004) 1324-1332
33. Barrios-Rodiles M., et al. High-throughput mapping of a dynamic signaling network in mammalian cells. Science 307 (2005) 1621-1625
34. Bouwmeester T., et al. A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway. Nat. Cell Biol. 6 (2004) 97-105
35. Lim J., et al. A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. Cell 125 (2006) 801-814
36. Chen H.K., et al. Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell 113 (2003) 457-468
37. Gandhi T.K., et al. Analysis of the human protein interactome and comparison with yeast, worm and fly interaction datasets. Nat. Genet. 38 (2006) 285-293
38. Green D.R., and Chipuk J.E. p53 and metabolism: Inside the TIGAR. Cell 126 (2006) 30-32
39. Toledo F., and Wahl G.M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 6 (2006) 909-923
40. Vassilev L.T., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 (2004) 844-848
41. Vassilev L.T. MDM2 inhibitors for cancer therapy. Trends Mol. Med. 13 (2007) 23-31
42. Meulmeester E., et al. Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol. Cell 18 (2005) 565-576
43. Inoki K., and Guan K.L. Complexity of the TOR signaling network. Trends Cell Biol. 16 (2006) 206-212
44. Frias M.A., et al. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr. Biol. 16 (2006) 1865-1870
45. Jacinto E., et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127 (2006) 125-137
46. Haar E.V., et al. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell Biol. 9 (2007) 316-323
47. Sancak Y., et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell 25 (2007) 903-915
48. Wang L., et al. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol. Chem. 282 (2007) 20036-20044
49. Hart G.T., et al. How complete are current yeast and human protein-interaction networks?. Genome Biol. 7 (2006) 120